1. Immunohistochemical evaluation of vasopressin expresion in breast fibrocystic disease and ductal carcinoma In situ (DCIS)
- Author
-
Wendy A. Wells, Vincent A. Memoli, Rennie S. Mathew, William G. North, Michael J. Fay, and Edward M. Donnelly
- Subjects
Pathology ,medicine.medical_specialty ,Vasopressin ,Fibrocystic Breast Disease ,Vasopressins ,Biopsy ,Endocrinology, Diabetes and Metabolism ,Breast Neoplasms ,Pathology and Forensic Medicine ,Endocrinology ,Ductal carcinoma in situ (DCIS) ,Gene expression ,medicine ,Humans ,skin and connective tissue diseases ,Gene ,Retrospective Studies ,biology ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Immunohistochemistry ,Carcinoma, Ductal ,Gene Expression Regulation, Neoplastic ,biology.protein ,Female ,Antibody ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
We previously found that expression of the vasopressin gene is a common feature of human breast cancer. In the present study we first examined 21 different cases of benign fibrocystic breast disease for vasopressin expression using immunohistochemistry and antibodies directed against vasopressin (anti-VP) and against vasopressin-associated glycopeptide (anti-VAG). All cases examined were negative for vasopressin gene expression using these antibodies. Alternatively, we examined 16 cases of breast ductal carcinoma in situ (DCIS) using the second of these antibodies (anti-VAG), and all of these cases were positive for vasopressin gene expression. Our results suggest that products of vasopressin gene expression are not markers of cellular proliferation in the breast, and might rather represent an early part of the carcinogenic process in this tissue.
- Published
- 2003
- Full Text
- View/download PDF